Heptares Therapeutics Limited – Product Pipeline Review

Global Markets Direct’s, ‘Heptares Therapeutics Limited – Product Pipeline Review – 2016’, provides an overview of the Heptares Therapeutics Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Heptares Therapeutics Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Heptares Therapeutics Limited

The report provides overview of Heptares Therapeutics Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Heptares Therapeutics Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Heptares Therapeutics Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Heptares Therapeutics Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Heptares Therapeutics Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Heptares Therapeutics Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Heptares Therapeutics Limited Snapshot 6

Heptares Therapeutics Limited Overview 6

Key Information 6

Key Facts 6

Heptares Therapeutics Limited - Research and Development Overview 7

Key Therapeutic Areas 7

Heptares Therapeutics Limited - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Heptares Therapeutics Limited - Pipeline Products Glance 14

Heptares Therapeutics Limited - Clinical Stage Pipeline Products 14

Phase I Products/Combination Treatment Modalities 14

Heptares Therapeutics Limited - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Heptares Therapeutics Limited - Drug Profiles 17

HTL-9936 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

HTL-1071 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

HTL-14242 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

HTL-6641 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecule to Agonize GPR39 for Type 1 and Type 2 Diabetes 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody to Antagonize GPCR for Inflammation 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody to Target GPCR for Undisclosed Indications 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Antagonize CXCR4 for Cancer and HIV 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule to Target GPCR for CNS Disorders 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecule to Target mGluR2 for Schizophrenia 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecules to Target GPCR for Pain, Cardiovascular, Metabolic and Inflammatory Disorders 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Heptares Therapeutics Limited - Pipeline Analysis 33

Heptares Therapeutics Limited - Pipeline Products by Target 33

Heptares Therapeutics Limited - Pipeline Products by Route of Administration 34

Heptares Therapeutics Limited - Pipeline Products by Molecule Type 35

Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action 36

Heptares Therapeutics Limited - Recent Pipeline Updates 37

Heptares Therapeutics Limited - Dormant Projects 42

Heptares Therapeutics Limited - Locations And Subsidiaries 43

Head Office 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Heptares Therapeutics Limited, Key Information 6

Heptares Therapeutics Limited, Key Facts 6

Heptares Therapeutics Limited – Pipeline by Indication, 2016 8

Heptares Therapeutics Limited – Pipeline by Stage of Development, 2016 10

Heptares Therapeutics Limited – Monotherapy Products in Pipeline, 2016 11

Heptares Therapeutics Limited – Out-Licensed Products in Pipeline, 2016 12

Heptares Therapeutics Limited – Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Heptares Therapeutics Limited – Phase I, 2016 14

Heptares Therapeutics Limited – Preclinical, 2016 15

Heptares Therapeutics Limited – Discovery, 2016 16

Heptares Therapeutics Limited – Pipeline by Target, 2016 33

Heptares Therapeutics Limited – Pipeline by Route of Administration, 2016 34

Heptares Therapeutics Limited – Pipeline by Molecule Type, 2016 35

Heptares Therapeutics Limited – Pipeline Products by Mechanism of Action, 2016 36

Heptares Therapeutics Limited – Recent Pipeline Updates, 2016 37

Heptares Therapeutics Limited – Dormant Developmental Projects,2016 42

List of Figures

List of Figures

Heptares Therapeutics Limited – Pipeline by Top 10 Indication, 2016 8

Heptares Therapeutics Limited – Pipeline by Stage of Development, 2016 10

Heptares Therapeutics Limited – Monotherapy Products in Pipeline, 2016 11

Heptares Therapeutics Limited – Out-Licensed Products in Pipeline, 2016 12

Heptares Therapeutics Limited – Pipeline by Top 10 Target, 2016 33

Heptares Therapeutics Limited – Pipeline by Route of Administration, 2016 34

Heptares Therapeutics Limited – Pipeline by Molecule Type, 2016 35

Heptares Therapeutics Limited – Pipeline Products by Top 10 Mechanism of Action, 2016 36

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports